Build status - In Progress

Healey ALS Platform Trial - Regimen F ABBV-CLS-7262

Recruiting
18 years - 100 years
All
Phase 2
2 participants needed
1 Location

Brief description of study

ABBV-CLS-7262 is a prodrug that is converted in vivo to the pharmacologically active parent compound A-1684909. A-1684909 is a central nervous system (CNS)-penetrant, eukaryotic translation initiation factor 2B (eIF2B) activator that attenuates the integrated stress response (ISR), a highly conserved cellular mechanism hypothesized to be important in the pathophysiology of amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions when activated chronically (Costa-Mattioli et al. 2020).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Amyotrophic Lateral Sclerosis,ALS
  • Age: 18 years - 100 years
  • Gender: All

Confirmed ALS diagnosis; greater than 50% FVC or SVC; less than 36 months since symptom onset; must either be not taking, or on a stable dose of Riluzole, Edaravone (Radicava), or Relyvrio

Updated on 04 Aug 2024. Study ID: 842770F

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center